Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

Ibex Biosciences engages in a diverse approach to research and development. Ibex strives to discover, validate, and produce potential solutions to a multitude of serious challenges facing human and ecological health by investing in exploratory projects and processes that may not have been validated within the public research community. The company develops therapeutic antibodies, gene therapy, and stem cell programs intended to address unmet medical conditions plaguing humanity. Its robust portfolio focuses on three primary areas: (1) cancer and non-cancer therapeutic antibodies/intrabody: Ibex is producing and developing antibodies targeting multiple cancers including breast, prostate, glioblastoma, lung, and neuroblastoma; (2) Cancer Gene Therapy: Ibex is developing a gene therapy that targets multiple cancer cells in-vitro including glioblastoma, melanoma, and cervical; and (3) Diagnostic Antibodies: Ibex is developing a skin cancer initial diagnostic, a CIN (Cervical Intraepithelial Neoplasia) diagnostic, and an early-stage pancreatic cancer diagnostic. It was founded in 2015 and is headquartered in Cumberland, Maryland.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Traxxsson is a biotechnology company that develops diagnostics for cancer using protein biomarkers. It uses a proprietary panel of biomarkers to identify at-risk patients who have questionable radiology images. It has three tests: PRO CancSure to identify prostate cancer patients in need of aggressive treatment, BRE CancSure to confirm the presence of breast cancer in women with positive mammograms, and LNG CancSure to confirm the presence of lung cancer in patients with positive low-density CAT scan results. The company was founded in 2009 and is based in St. Louis, Missouri.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Syntekabio is a Korean biotech firm, developing personal genome map which is expected to enable personalized medical service. The company also provides a technology for collecting and integrating decrypted whole genome data.

Cytyc Corporation, a diagnostic and medical device company, designs, develops, manufactures, and markets and diagnostic and surgical products. The company offers its products for a range of cancer and women's health applications, such as cervical cancer screening, menstrual bleeding treatment, early-stage breast cancer radiation treatment, and malignant brain tumors radiation treatment applications. It serves customers in the Canadian, European, and Asia/Pacific markets. The company was founded in 1987 and is based in Marlborough, Massachusetts. As of October 22, 2007, CYTYC Corporation opeartes as a subsidiary of Hologic Inc.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Ciphergen Biosystems KK markets and supplies protein chip systems and services for clinical, research and process proteomic applications. The company was founded in January, 1999 and is headquartered in Yokohama, Japan.

Konkuk University Industry-Academic Cooperation Foundation increases the competitiveness of industries by linking company and university.

BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world.